NCT04967170已完成1 期
A Pilot, Randomized, Blinded, Controlled Study Evaluating Autologous Platelet-Rich Plasma for the Treatment of Vulvar Lichen Sclerosus
Jennifer R. Arthurs1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2022年1月19日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Incidence of adverse events
研究概览
简要总结
The purposes of this study are to determine the safety and feasibility of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus, and to determine the efficacy of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female, ages 18 years and greater.
- •Females of childbearing potential must have a negative pregnancy test prior to receiving the study drug and will agree to use adequate contraception (hormonal or barrier method or abstinence) from the time of screening to a period of 1 year following completion of the drug treatment cycle. Females of childbearing potential are defined as premenopausal and not surgically sterilized, or post-menopausal for fewer than 2 years. A urine pregnancy test will be performed prior to the administration of the study drug to confirm negative results. If the urine pregnancy test is positive, the study drug will not be administered and the result will be confirmed by a serum pregnancy test. Serum pregnancy tests will be performed at a central clinical laboratory, whereas urine pregnancy tests will be performed by qualified personnel using kit.
- •Females becoming pregnant during the study will continue to be monitored for the duration of the study or completion of the pregnancy, whichever is longer. Monitoring will include perinatal and neonatal outcome. Any SAEs associated with pregnancy will be recorded.
- •Diagnosis of Lichen Sclerosus.
- •On a maintenance regimen of topical clobetasol for Lichen Sclerosus. Maintenance is defined as use of topical clobetasol 3 or fewer days per week. For patients with a new diagnosis of Lichen Sclerosus, they will complete 6 weeks of topical clobetasol ointment twice daily prior to enrollment in the study with transition to a maintenance regimen during study.
- •Completed general physical evaluation with primary care provider within 12 months of enrollment.
- •Full understanding of the requirements of the study and willingness to comply with protocol.
- •Can provide written informed consent and complete HIPAA documentation after the nature of the study is fully explained and prior to any study-related procedure
排除标准
- •Pregnant or nursing, or planning on becoming pregnant during the study period.
- •Clinically significant abnormal hematology (complete blood count with differential).
- •Taking anticoagulant medications (e.g., warfarin, heparin) or clopidogrel (Plavix).
- •Taking anti-rheumatic disease medication (including methotrexate or other antimetabolites) within 3 months prior to study enrollment.
- •On chronic, immunosuppressive transplant therapy or having a chronic, immunosuppressive state, including use of systemic steroids/corticosteroids.
- •Using topical steroids on affected area and unable to stop for the 6 week washout period prior to beginning the study. Topical steroid use will be exclusionary throughout week 12 of the study for patients randomized to receive PRP.
- •Current tobacco product use, including nicotine patch or other nicotine products.
- •Ongoing infectious disease, including but not limited to tuberculosis, HIV, hepatitis, and syphilis.
- •Clinically significant cardiovascular (e.g., history of myocardial infarction, congestive heart failure or uncontrolled hypertension > 90 mmHg diastolic and/or 180 mmHg systolic), neurologic (e.g., stroke, TIA) renal, hepatic, or endocrine disease (e.g., diabetes).
- •History of cancer/malignancy with the exception of adequately treated basal cell or squamous cell carcinoma of the skin within the last 5 years.
- •History of blood dyscrasia, including but not limited to anemia, thrombocytopenia, and monoclonal gammopathy.
- •Participation in a study of an experimental drug or medical device within 3 months of study enrollment.
- •Known allergy to local anesthetics of other components of the study drug.
- •History of or current evidence of alcohol or drug abuse or dependence, recreational use of illicit drug or prescription medications, or have use of medical marijuana within 30 days of study entry.
- •Any illness or condition which, in the investigators' judgement will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results.
研究组 & 干预措施
Platelet Rich Plasma Group
Experimental
Subject diagnosed with vulvar lichen sclerosus will receive Autologous Platelet-Rich Plasma (PRP)
干预措施: Autologous Platelet-Rich Plasma (PRP) (Biological)
Sham Procedure Group
Sham Comparator
Subject diagnosed with vulvar lichen sclerosus will receive sham procedure of intralesional needle insertion without any injectate administered.
干预措施: Sham Procedure (Other)
结局指标
主要结局
Incidence of adverse events
时间窗: 6 months
Number of adverse events reported
次要结局
- Change in patient-administered symptom score on Clinical Scoring System for Lichen Sclerosus(Baseline, 1 week, 6 weeks, 12 weeks, 3 months, 6 months)
研究者
Jennifer R. Arthurs
Sponsor-Investigator
Mayo Clinic
研究点 (1)
Loading locations...
相似试验
已完成
早期 1 期
Platelet-Rich Plasma (PRP) for Treatment of Symptomatic Lumbar Facet Syndrome of the SpinePlatelet-Rich PlasmaNCT04522674University of Colorado, Denver5
已完成
不适用
Prospective Trial of Autologous Platelet Rich Plasma in Aortic SurgeryC.Surgical Procedure CardiacNCT02513862Hongwen Ji80
已完成
2 期
Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound HealingDupuytren's ContractureNCT00931567Centre Hospitalier Universitaire de Nice80
已完成
1 期
PRP for the Treatment of Erectile Dysfunction (ED)Erectile DysfunctionNCT04350125Mayo Clinic4
撤回
2 期
The Effect of Platelet-rich Plasma in Subjects With Androgenetic AlopeciaAndrogenetic AlopeciaNCT03048461Northwestern University